ViewsML / coverage
About
| Virtual biomarker staining is a new idea for many pathologists, and the companies that explain it first help define the category. ViewsML wanted to be one of those voices.
SVM coordinated a Q&A opportunity for ViewsML with The Pathologist, a publication read by practicing pathologists and laboratory professionals. The article, on virtual staining in the tumor microenvironment, ran in the April 2026 issue and placed ViewsML at the forefront of the discussion. The Q&A opened a sustained thought leadership program in The Pathologist, followed by a bylined article from CEO Kenneth To in June 2026. |
